Dermira is committed to constant innovation in the field of medical dermatology and recognizes the contribution of investigator-initiated studies (IIS) toward this goal. We recognize the critical role IIS can play in the overall expansion of medical knowledge and in generation of further research avenues to improve treatments for patients affected by chronic skin conditions. Dermira supports IIS efforts through providing drug product, funding or both.
Investigator-Initiated Studies (IIS)
- Scientific and medical merit
- Alignment with Dermira strategic priorities and vision
- Feasibility of study protocol
- Reasonableness of study budget
Dermira, Inc. is committed to compliance with all applicable federal and state pharmaceutical industry laws, regulations, and industry guidelines. Submission of this concept application does not constitute or represent a funding commitment by Dermira, Inc. Such a funding decision is subject to Dermira Inc.’s internal approval of an IIS Full Application, if so invited of the Requestor. This IIS Full Application may in turn be approved or denied subject Dermira, Inc.’s sole and absolute discretion. Dermira Inc.’s financial and/or product support is contingent upon full execution by both parties of a written Dermira Grant Agreement.
To inquire directly about current areas of interest and for any other questions, please contact us at firstname.lastname@example.org.